Tashkent Stock Exchange (UZSE) · Common share · Consumer Staples
Biokimyo AJ (BIOK) shares
Biokimyo AJ is listed on the Tashkent Stock Exchange (UZSE), Uzbekistan's stock exchange, under the ticker BIOK (ISIN UZ7025870005). This page shows its latest trade, a year of daily prices, reported financials and recent disclosures.
Last trade
14,220 UZS
−180 (−1.25%)since Nov 2, 2026, the previous recorded trade
Price as of Nov 3, 2026. Not a live quote. Source: uzse.uz.
Nov 3, 2026Latest
- Open
- 15,000.00
- High
- 15,000.00
- Low
- 14,130.00
- Close
- 14,220.00
- Change
- −180.00(−1.25%)
- Volume, shares
- 3,775
- Turnover, UZS
- 53,453,875.07
Low 13,950 UZS · High 18,400 UZS
Hover, tap or use the arrow keys to see a session's figures.
Key figures
- Market capitalizationthis share class
- 81.24 bln UZS
- P/ENov 3, 2026
- 6.14
- P/B
- 0.69
- ROE2025
- 11.17%
- Dividend per share2025
- 100 UZS
- Price range237 days
- 14,
220 UZS
P/E and P/B use the close of Nov 3, 2026 and the latest reported annual figures.
Last session
- Previous close
- 14,400 UZS
- Open
- 15,000 UZS
- High
- 15,000 UZS
- Low
- 14,130 UZS
- Volume
- 3,775
Fundamentals
- Shares outstandingthis share class
- 5,713,280
- Net revenue2025
- 225.44 bln UZS
- Net profit2025
- 13.24 bln UZS
- Total assets2025
- 128.53 bln UZS
Ownership and management
Shareholders and management appear here once the issuer reports them on openinfo.uz.
Security details
- Ticker
- BIOK
- ISIN
- UZ7025870005
- Share class
- Common share
- Exchange
- Tashkent Stock Exchange (UZSE)
- Sector
- Consumer Staples
- Industry
- Distillers & Vintners
- Currency
- UZS
Other Consumer Staples shares on UZSE
Shares Finmind tracks in the same sector, most recently traded first.
Reported history
FY2016 to FY2025: 10 years
- Net revenueFY2025
- 225.44 bln UZS
- Net incomeFY2025
- 13.24 bln UZS
- Earnings per shareFY2025
- 2,
317.59 UZS - Dividend per shareFY2025
- 100 UZS
- Payout ratioFY2025
- 4.31%
- Debt to equityFY2025
- 0.08×
Per-share figures divide each year's reported profit by the share count as of Oct. 31, 2026; a later share issue or split would change them.
| Fiscal year | Net revenue |
|---|---|
| FY2016 | 55.14 bln UZS |
| FY2017 | 68.35 bln UZS |
| FY2018 | 95.52 bln UZS |
| FY2019 | 137.51 bln UZS |
| FY2020 | 191.63 bln UZS |
| FY2021 | 211.61 bln UZS |
| FY2022 | 277.44 bln UZS |
| FY2023 | 276.37 bln UZS |
| FY2024 | 238.09 bln UZS |
| FY2025 | 225.44 bln UZS |
| Fiscal year | Net income |
|---|---|
| FY2016 | 4.43 bln UZS |
| FY2017 | 6.5 bln UZS |
| FY2018 | 8.77 bln UZS |
| FY2019 | 14.96 bln UZS |
| FY2020 | 23.37 bln UZS |
| FY2021 | 23.5 bln UZS |
| FY2022 | 28.71 bln UZS |
| FY2023 | 45.04 bln UZS |
| FY2024 | 31.98 bln UZS |
| FY2025 | 13.24 bln UZS |
| Fiscal year | Dividend per common share |
|---|---|
| FY2016 | 1,550 UZS |
| FY2017 | 1,850 UZS |
| FY2018 | 1,540 UZS |
| FY2019 | 4,454 UZS |
| FY2020 | 6,140 UZS |
| FY2021 | no dividend declared for this year |
| FY2022 | 8,725 UZS |
| FY2023 | 2,400 UZS |
| FY2024 | 1,000 UZS |
| FY2025 | 100 UZS |
| Fiscal year | Revenue growth |
|---|---|
| FY2016 | +28.81% |
| FY2017 | +23.96% |
| FY2018 | +39.76% |
| FY2019 | +43.96% |
| FY2020 | +39.35% |
| FY2021 | +10.43% |
| FY2022 | +31.11% |
| FY2023 | −0.39% |
| FY2024 | −13.85% |
| FY2025 | −5.32% |
| Fiscal year | Earnings per share |
|---|---|
| FY2016 | 775.07 UZS |
| FY2017 | 1,137.52 UZS |
| FY2018 | 1,535.55 UZS |
| FY2019 | 2,618.98 UZS |
| FY2020 | 4,091.12 UZS |
| FY2021 | 4,114.07 UZS |
| FY2022 | 5,025.45 UZS |
| FY2023 | 7,882.55 UZS |
| FY2024 | 5,597.26 UZS |
| FY2025 | 2,317.59 UZS |
| Fiscal year | Debt to equity, percent of equity |
|---|---|
| FY2016 | 30.20% |
| FY2017 | 23.31% |
| FY2018 | 5.22% |
| FY2019 | 6.23% |
| FY2020 | 9.84% |
| FY2021 | 23.86% |
| FY2022 | 23.50% |
| FY2023 | 1.14% |
| FY2024 | 23.57% |
| FY2025 | 8.39% |
Free cash flow: not reported
As of Nov 4, 2026 · Source: annual financial statements filed on openinfo.uz, and the dividend calendar.
Disclosures
2 filings, newest first
- Квартальный отчет Акционерного общества (opens in a new tab)
Quarterly report
- Квартальный отчет Акционерного общества (opens in a new tab)
Quarterly report
Source: openinfo.uz, in the language the issuer filed. Dates are Tashkent time.
Go deeper on BIOK in Finmind
A free Finmind account adds portfolio tracking from your broker's statements, orders through your own brokerage account, the market-wide order book and a practice simulator. Premium adds valuation, the tax declaration and stop-loss orders.